Nancy Valente Net Worth

The estimated Net Worth of Nancy Valente is at least $1.6 Milhão dollars as of 2 May 2024. Nancy Valente owns over 4,745 units of Myovant Sciences Ltd stock worth over $1,487,003 and over the last 3 years Nancy sold MYOV stock worth over $111,887.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Nancy Valente MYOV stock SEC Form 4 insiders trading

Nancy has made over 1 trades of the Myovant Sciences Ltd stock since 2024, according to the Form 4 filled with the SEC. Most recently Nancy sold 4,745 units of MYOV stock worth $111,887 on 2 May 2024.

The largest trade Nancy's ever made was selling 4,745 units of Myovant Sciences Ltd stock on 2 May 2024 worth over $111,887. On average, Nancy trades about 678 units every 0 days since 2021. As of 2 May 2024 Nancy still owns at least 55,115 units of Myovant Sciences Ltd stock.

You can see the complete history of Nancy Valente stock trades at the bottom of the page.

What's Nancy Valente's mailing address?

Nancy's mailing address filed with the SEC is C/O XENCOR, INC., 465 N HALSTEAD STREET, SUITE 200, PASADENA, CA, 91107.

Insiders trading at Myovant Sciences Ltd

Over the last 8 years, insiders at Myovant Sciences Ltd have traded over $5,780,890 worth of Myovant Sciences Ltd stock and bought 96,585,963 units worth $2,001,605,371 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ..., eAndrew Lo. On average, Myovant Sciences Ltd executives and independent directors trade stock every 15 days with the average trade being worth of $25,106,967. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 10 March 2023, trading 51,599,200 units of MYOV stock currently worth $1,393,178,400.

What does Myovant Sciences Ltd do?

Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.

Complete history of Nancy Valente stock trades at Xencor Inc e Myovant Sciences Ltd

Myovant Sciences Ltd executives and stock owners

Myovant Sciences Ltd executives and other stock owners filed with the SEC include:

• Lynn Seely,
  Principal Executive Officer, Director
• Matthew Lang,
  General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc.
• Frank Karbe,
  Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc.
• Juan Camilo Arjona Ferreira,
  Chief Commercial Officer - Myovant Sciences, Inc
• David C. Marek,
  CEO & Director
• Matthew Lang J.D.,
  Gen. Counsel & Corp. Sec.
• Kathleen Sebelius,
  Lead Independent Director
• Myrtle Potter,
  Chairman of the Board
• Mark Guinan,
  Independent Director
• Terrie Curran,
  Independent Director
• Adele Gulfo,
  Director, Interim Chief Commercial Officer
• Hiroshi Nomura,
  Director
• Dr. Andria Langenberg M.D.,
  Head of Drug Safety & Pharmacovigilance
• Dr. Teresa Perney Ph.D.,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Dr. Juan Camilo Arjona Ferreira M.D.,
  Chief Medical Officer
• Bryan Selby,
  Sr. VP of Product Devel.
• Julie Tran MBA, MSHR,
  Sr. VP of HR
• Albert Liao,
  Director of Corp. Communications
• Ryan Crowe,
  VP of Investor Relations
• Uneek Mehra,
  Chief Financial & Bus. Officer
• Kim Sablich,
  Chief Commercial Officer
• Uneek Mehra,
  Principal Financial Officer
• David C Marek,
  Principal Executive Officer
• Wayne S De Veydt,
  Director
• Mark Altmeyer,
  Director
• Pharmaceuticals Internation...,
  10% owner
• Global Investors Lp Viking ...,
  
• Holdings Ltd.Dexcel Pharma ...,
  
• Global Performance Llc Viki...,
  
• Investments (Uk) Ltd Soft B...,
  
• Sciences Ltd. Roivant,
  10% owner
• Patrick Machado,
  
• Associates Gp Llcqvt Fund V...,
  
• Global Performance Llc Viki...,
  
• Pharmaceuticals Internation...,
  
• Frank Torti,
  Director
• Chemical Co., Ltd.Sumitomo ...,
  
• Lauren Merendino,
  Chief Commercial Officer
• Nancy Valente,
  Director